Moderna Stock News

The Russia-Ukraine war is unlikely to interrupt the supply of COVID-19 vaccines to Africa in the short term, the World Health Organization said on Thursday. The reason isn’t far-fetched. Russia’s Sputnik vaccine has remained a minimal segment of imports to plug the vaccine gap on the continent. There have been concerns that the global shift in focus to the war which is now in its second week could interrupt vaccine shipments to Africa, dampening WHO’s prospects for the year. Forecasts by the global health body in February pointed to a positive supply outlook, with COVAX securing enough vaccines to achieve 45 percent of coverage across countries by the middle of this year. AstraZeneca, Pfizer, Moderna and Johnson & Johnson vaccines constitute the majority of these supplies. The use of the Russian vaccine is still limited despite being registered in 15 African countries. Read also: COVID-19 vaccination improves mental health Sputnik V is also set back by the lack of emergency use authorisation from the WHO and other important independent regulatory bodies in countries like South Africa.

Moderna (MRNA) will open an enterprise solutions hub in Atlanta to handle finance, human resources, procurement, and digital functions.

AMSTERDAM - The European Medicines Agency said it has authorized Moderna''s coronavirus vaccine for children aged six to 11, in addition to recommending booster shots of…

Moderna, Inc. (NASDAQ:MRNA) is a biotechnology company that creates therapeutics and vaccines to treat infectious and rare diseases, immuno-oncology, cardiovascular diseases, and autoimmune diseases.

The European Medicines Agency said it has authorized Moderna’s coronavirus vaccine for children aged six to 11, in addition to recommending booster shots of Pfizer’s vaccine for those aged 12 and over

Shares of Pfizer Inc. gained 0.6% in premarket trading on Wednesday after the company said its experimental respiratory syncytial virus (RSV) vaccine had received a breakthrough therapy designation from the Food and Drug Administration. The vaccine candidate is being evaluated in pregnant women to see if it can prevent illness among infants up to until the age of 6 months old. Several drug makers are developing RSV vaccines, including Moderna Inc. and GlaxoSmithKline , though GSK this week halted a study assessing its investigational RSV shot in pregnant women, saying it needs to better understand the safety data. Pfizer''s stock has gained 36.5% over the past year, while the broader S&P 500 is up 10.3%. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

It has to do with the whole picture.

Two biotechnology companies filed a lawsuit against Moderna this week and alleged the vaccine manufacturer infringed on patented technology in the development of its commonly used COVID-19 shot. Arbutus Biopharma and Genevant Sciences, the companies, claim in a civil lawsuit that Moderna used “breakthrough technology Arbutus had already created and patented” to create the COVID-19 […]

It''s not likely, but it could still end up being a good investment.

Since late 2020, the inequitable access across the globe to COVID-19 vaccines has been a glaring problem. But a remarkable achievement earlier this month offers hope that the supply of vaccines to developing countries will improve: Afrigen Biologics, a South African based company, produced its own version of Moderna’s mRNA COVID-19 vaccine. This was achieved […]

Highlights Novavax, Inc. was working on its plan to introduce a single injection that protects against Covid-19 and seasonal flu. Novavax informed that it expects to launch the combo vaccine later this year. Many scientists have predicted that the Covid-19 booster dose will be required each year; therefore, pharmaceuticals companies are working on combing seasonal flu, and Covid-19 does. Clinical stage company, Novavax, Inc. ( NYSE:NVAX ) was already working its plan to introduce a single injection that protects against Covid-19 and seasonal flu. Novavax shared an update that it expects to launch a new trial of the combo vaccine later this year. Must read : Australian kids aged 6-11 can now get Moderna’s COVID-19 vaccine In the earnings call on Tuesday, Stanley Erck, CEO of Novavax, informed that it has brought its vaccine to the market. He also announced that the company had gained authorisation in 38 countries. Novavax work on the Covid-flu combo Since the beginning of the pandemic, Novavax has been working on developing the Covid-flu combo vaccine.

Moderna (MRNA) shares have been on the backfoot since the turn of the year but investors were evidently pleased with the company’s latest quarterly results, giving …

Moderna is being sued by two smaller, Vancouver-based, biotech firms that are alleging the company infringed on their copyright in making its vaccine by using patented nanoparticle technology.

A lawsuit filed Monday by Arbutus Biopharma Corp against Moderna Inc is the latest in a small but growing list of high-stakes patent disputes over COVID-19 vaccines and treatments.

Within the last quarter, Moderna (NASDAQ: MRNA ) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 0 0 7 2 0 Last 30D 0 0 1 0 0 1M Ago 0 0 1 1 0 2M Ago 0 0 4 1 0 3M Ago 0 0 1 0 0 In the last 3 months, 9 analysts have offered 12-month price targets for Moderna. The company has an average price target of $191.67 with a high of $315.00 and a low of $81.00. Below is a summary of how these 9 analysts rated Moderna over the past 3 months. The greater the number of bullish ratings, the more positive analysts are … Full story available on Benzinga.com